ALX Oncology Extends Cash Runway to Mid-2028 with $140M Offering, Reports Positive Clinical Data

summarizeSummary

ALX Oncology announced the completion of a $150 million equity offering, extending its cash runway through 1H 2028, alongside positive clinical biomarker data for evorpacept and progress in its pipeline.

check_boxKey Events

• Cash Runway Extended to Mid-2028

  The company completed a registered equity offering, generating $140.4 million in net proceeds, which is expected to fund operations through the first half of 2028. This follows the pricing of the offering announced on January 30, 2026.

• Positive Clinical Biomarker Validation

  Exploratory analyses from Phase 2 ASPEN-06 (gastric cancer) and Phase 1b/2 (HER2-positive breast cancer) trials validated CD47 overexpression as a predictive biomarker for evorpacept response and durable benefit.

• Pipeline Advancement and Trial Expansion

  The Phase 2 ASPEN-09 breast cancer trial, evaluating evorpacept efficacy by CD47 expression, has expanded enrollment from 80 to up to 120 patients, with topline data anticipated mid-2027. The Phase 1 ALX2004 trial is also progressing, with safety data from the dose-escalation phase expected in 2H 2026.

• Improved Financial Performance

  ALX Oncology reported a GAAP net loss of ($22.8) million for Q4 2025 and ($101.7) million for the full year 2025, representing a decrease in losses compared to the prior year periods.

auto_awesomeAnalysis

ALX Oncology has significantly strengthened its financial position and clinical outlook. The completion of a $150 million public offering, yielding $140.4 million in net proceeds, extends the company's cash runway through the first half of 2028. This provides crucial funding for ongoing clinical programs, substantially de-risking the company's near-term operations. Concurrently, the company reported positive biomarker validation for its lead candidate, evorpacept, in multiple cancer trials, reinforcing its targeted development strategy. Progress in both evorpacept and ALX2004 clinical trials, coupled with reduced net losses, indicates a positive trajectory for the clinical-stage biotechnology firm.